Clinical Trials in Minato-ku, Tokyo
28 recruiting
Showing 1–20 of 23 trials
Recruiting
Phase 3
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
Immunoglobulin A Nephropathy (IgAN)
Biogen454 enrolled233 locationsNCT06935357
Recruiting
Phase 3
A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease
Immunoglobulin G4-Related Disease
Sanofi124 enrolled68 locationsNCT07190196
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
Crohn's Disease
Merck Sharp & Dohme LLC1,200 enrolled499 locationsNCT06430801
Recruiting
Phase 3
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Solid TumorsHematologic Malignancies
Merck Sharp & Dohme LLC3,500 enrolled779 locationsNCT03486873
Recruiting
Phase 3
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
ObesityOverweightAtherosclerotic Cardiovascular Disease
Amgen12,800 enrolled759 locationsNCT07037433
Recruiting
Phase 3
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Metastatic Castration-resistant Prostate Cancer
Amgen750 enrolled125 locationsNCT07213674
Recruiting
Phase 3
Study of Out of Specification for Tisagenlecleucel
Diffuse Large B Cell LymphomaB-cell Acute Lymphoblastic Leukemia
Novartis Pharmaceuticals200 enrolled53 locationsNCT04094311
Recruiting
Phase 2
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis
Ulcerative Colitis
Takeda207 enrolled141 locationsNCT06254950
Recruiting
Study to Assess Change in Disease Activity of Risankizumab Treatment in Japanese Participants With Moderate to Severe Ulcerative Colitis
Ulcerative Colitis
AbbVie200 enrolled28 locationsNCT07136116
Recruiting
Specified Drug-use Surveillance of Fabhalta Capsules
Paroxysmal nocturnal hemoglobinuria
Novartis Pharmaceuticals100 enrolled92 locationsNCT06606314
Recruiting
Phase 2Phase 3
Study to Evaluate the Safety, PK, PD, and Efficacy of PRX-102 in Japanese Patients With Fabry Disease
Fabry Disease
Chiesi Farmaceutici S.p.A.16 enrolled10 locationsNCT05710692
Recruiting
Phase 3
A Study of Vortioxetine in Japanese Pediatric Patients With Major Depressive Disorder
Major Depressive Disorder
Takeda180 enrolled30 locationsNCT07204314
Recruiting
Phase 1
Study of KK3910 in Healthy Volunteers and Patients With Essential Hypertension
Healthy Volunteers Essential Hypertension
Kyowa Kirin Co., Ltd.160 enrolled3 locationsNCT06823947
Recruiting
Phase 2Phase 3
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
Neoplasms
Celgene1,541 enrolled200 locationsNCT03435796
Recruiting
Phase 3
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
Hidradenitis Suppurativa
AbbVie1,328 enrolled285 locationsNCT05889182
Recruiting
An Observational Study to Assess Change in Disease Activity and Adverse Events in Adolescent and Adult Participants With Moderate to Severe Active Crohn's Disease (CD) in Japan
Crohn's Disease
AbbVie240 enrolled104 locationsNCT06023030
Recruiting
Special Drug Use-results Surveillance of Tafinlar/Mekinist
BRAF V600E Mutation-positive Unresectable Advanced or Recurrent Solid Tumor
Novartis Pharmaceuticals110 enrolled68 locationsNCT06262919
Recruiting
Phase 3
Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)
EPPXLP
Tanabe Pharma America, Inc.301 enrolled51 locationsNCT05005975
Recruiting
Patient Reported Outcomes and Patient Voice Among Patients Diagnosed With Low Risk Myelodysplastic Syndrome (LR-MDS) or Unexplained Anemia In Japan
Myelodysplastic Syndrome (MDS)
Bristol-Myers Squibb50 enrolled1 locationNCT07008820
Recruiting
Not Applicable
A Clinical Study of the Paradise™ Renal Denervation System in Patients With Hypertension (RADIANCE-HTN DUO)
Cardiovascular DiseasesHypertensionVascular Diseases
Otsuka Medical Devices Co., Ltd. Japan154 enrolled51 locationsNCT05326230